Antithrombotic Effect of Crotalin, a Platelet Membrane Glycoprotein Ib Antagonist From Venom of Crotalus atrox
- 1 March 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 91 (5) , 1582-1589
- https://doi.org/10.1182/blood.v91.5.1582
Abstract
A potent platelet glycoprotein Ib (GPIb) antagonist, crotalin, with a molecular weight of 30 kD was purified from the snake venom ofCrotalus atrox. Crotalin specifically and dose dependently inhibited aggregation of human washed platelets induced by ristocetin with IC50 of 2.4 μg/mL (83 nmol/L). It was also active in inhibiting ristocetin-induced platelet aggregation of platelet-rich plasma (IC50, 6.3 μg/mL). 125I-crotalin bound to human platelets in a saturable and dose-dependent manner with a kd value of 3.2 ± 0.1 × 10−7 mol/L, and its binding site was estimated to be 58,632 ± 3,152 per platelet. Its binding was specifically inhibited by a monoclonal antibody, AP1 raised against platelet GPIb. Crotalin significantly prolonged the latent period in triggering platelet aggregation caused by low concentration of thrombin (0.03 U/mL), and inhibited thromboxane B2formation of platelets stimulated either by ristocetin plus von Willebrand factor (vWF), or by thrombin (0.03 U/mL). When crotalin was intravenously (IV) administered to mice at 100 to 300 μg/kg, a dose-dependent prolongation on tail bleeding time was observed. The duration of crotalin in prolonging tail bleeding time lasted for 4 hours as crotalin was given at 300 μg/kg. In addition, its in vivo antithrombotic activity was evidenced by prolonging the latent period in inducing platelet-rich thrombus formation by irradiating the mesenteric venules of the fluorescein sodium-treated mice. When administered IV at 100 to 300 μg/kg, crotalin dose dependently prolonged the time lapse in inducing platelet-rich thrombus formation. In conclusion, crotalin specifically inhibited vWF-induced platelet agglutination in the presence of ristocetin because crotalin selectively bound to platelet surface receptor-glycoprotein Ib, resulting in the blockade of the interaction of vWF with platelet membrane GPIb. In addition, crotalin is a potent antithrombotic agent because it pronouncedly blocked platelet plug formation in vivo.Keywords
This publication has 42 references indexed in Scilit:
- Platelet GPIb-V-IX ComplexSeminars in Thrombosis and Hemostasis, 1995
- New Antiplatelet Agents: Platelet GPIIb/llla AntagonistsThrombosis and Haemostasis, 1995
- Antiplatelet protease, kistomin, selectively cleaves human platelet glycoprotein IbBiochimica et Biophysica Acta (BBA) - General Subjects, 1993
- Platelets and blood vessels: the adhesion eventImmunology Today, 1992
- Development of GPIIb/IIIa antagonists as antithrombotic drugsTrends in Pharmacological Sciences, 1992
- PLATELET ADHESIONBritish Journal of Haematology, 1990
- Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.Circulation, 1989
- Role of Platelet Membrane Glycoproteins and Von Willebrand Factor in Adhesion of Platelets to Subendothelium and CollagenAnnals of the New York Academy of Sciences, 1987
- Adhesion of Blood Platelets to the Extracellular Matrix of Cultured Human Endothelial CellsAnnals of the New York Academy of Sciences, 1987
- ThrombinaAnnals of the New York Academy of Sciences, 1986